Daclatasvir combo gets Breakthrough status

Share this article:

Bristol-Myers Squibb landed a Breakthrough Therapy designation for its daclatasvir + asunaprevir combination to treat genotype 1b hep. C. The regulator granted the designation based on Phase-III clinical data involving the all-oral, two-drug regimen.

If the drug mix sounds familiar, it is: the FDA granted Breakthrough Therapy status in October 2013 to an all-oral combination of daclatasvir, asunaprevir and BMS-791325, which is being studied in non-cirrhotic, treatment-naïve and experienced patients, as well as cirrhotic, treatment naïve and experienced patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.